Workflow
基石药业-B(02616)发布中期业绩,研发开支1.05亿元 同比增加58.75%
CSTONE PHARMACSTONE PHARMA(HK:02616) 智通财经网·2025-08-14 11:15

Group 1 - The company reported a revenue of RMB 49.451 million for the six months ending June 30, 2025, representing a year-on-year decrease of 80.54% [1] - Research and development expenses increased to RMB 105 million, a year-on-year increase of 58.75% [1] - The company incurred a loss of RMB 270 million during the period, with a basic loss per share of RMB 0.21 [1] Group 2 - Revenue sources included drug sales (Avaratinib and Pralsetinib) amounting to RMB 20 million, licensing fee income of RMB 17.9 million, and royalties from Sugli monoclonal antibody of RMB 11.3 million [1] - The significant decline in Pralsetinib sales was attributed to price adjustments and one-time channel compensation in preparation for negotiations for inclusion in the National Medical Insurance Drug List [1] - The company anticipates that if Pralsetinib is included in the National Medical Insurance Drug List, the sales growth benefits in 2026 and beyond will offset the short-term negative impact on revenue [1] Group 3 - The company accelerated its global expansion strategy and advanced its differentiated pipeline while strengthening its business landscape through strategic partnerships [2] - Significant achievements were made in regulatory approvals, clinical progress, and strategic collaborations during this period, reinforcing the company's position in innovative therapies [2]